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 A Qualitative And Quantitative Review of  
Behavioral Activation  
Treatment of Major Depressive Disorder 
 
C. Richard Spates, Ph.D., Sherry Pagoto, Ph.D., and Alyssa Kalata, B.A. 
 
 
  In the treatment of Major Depressive Disorder (MDD), Behavioral Activation Therapy (BA) 
 has emerged in recent years as an efficacious intervention. Derived from a component analysis  
of CBT, it offered at once a parsimonious explanation for the active ingredient of CBT, while  
demonstrating clinical efficacy as a separate treatment.  Since the original investigation by  
Jacobson and colleagues in 1996, several well-controlled studies have been conducted, all  
of which converge to suggest strong support for BA as a stand-alone therapy for MDD.  In this  
paper we review, evaluate and classify the evidence pertinent to this intervention and provide 
recommendations concerning its standing as a front line treatment. We conclude that the evidence  
is strong, the quality of research is generally very good and the effects sizes are compelling.  
Through both a qualitative and meta-analytic review of this evidence we also suggest the types  
of future studies that will establish greater confidence in BA as a front line treatment of choice 
therapy for Major Depressive Disorder.   
Key Terms: Behavioral Activation, Major Depressive Disorder, Cognitive Behavior Therapy,  
Efficacious Treatment 
 
 
Major Depressive Disorder (MDD) affects approximately 121 million people worldwide (World 
Health Organization, 2006).  In the United States, MDD has a lifetime prevalence of 10% to 25% for 
women and 5% to 12% for men and a point prevalence of 5% to 9% for women and 2% to 3% for men 
(American Psychiatric Association, 2000).  It has been determined to be the leading cause of disability 
and the 4th leading contributor to the global burden of disease (World Health Organization, 2006).  
Despite both the high prevalence and serious costs of depression, up to 90% of depressed patients in 
primary care settings fail to receive adequate treatment, in the form of empirically supported medication 
regimens or in the form of empirically supported psychotherapies for depression (Center for the 
Advancement of Health, 2000).  
 
  Of the available psychological therapies for treating MDD. Cognitive-Behavior Therapy (CBT) 
has emerged as the frontline treatment of choice, based on empirical findings demonstrating its efficacy 
and effectiveness.  Dobson (1989) conducted a meta-analysis of the literature investigating Beck’s 
Cognitive Therapy (CT) for depression (which is classified as Cognitive-Behavioral Therapy) and found 
that CT is more effective than general psychotherapy, Behavior Therapy, and pharmacotherapy in the 
treatment of MDD.  Based in part on Dobson’s conclusions, Chambless and colleagues (1998) labeled 
Cognitive Therapy (CT) for depression as a “well-established treatment.”  Recently, a component of CBT 
called Behavioral Activation (BA) has received a great deal of attention. First, because as a result of a 
component analysis it appeared to offer a conceptually parsimonious accounting of the measured effects 
of CBT.  Secondly it offered potential as a more efficient and thus, cost-effective treatment for MDD. 
Both of these observations resulted from the work of Jacobson and colleagues (1996). For this reason the 
National Institute of Mental Health called for greater research attention to this technique (NIMH vision 
statement, 2005). 
 
Although BA has a strong theoretical foundation (Lewinsohn, Sullivan, & Grosscup, 1980) and 
the packaged therapy from which it is derived (CBT) has strong empirical support, the studies devoted to 
the efficacy and effectiveness of BA as a stand-alone therapy, although encouraging, are somewhat 
limited.  An extensive review of the PsychInfo database yielded eleven treatment relevant studies devoted 
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to behavioral activation, two of which were case studies (Hopko, Lejuez, & Hopko, 2004; Mulick & 
Naugle, 2004). One of the remaining investigations constituted a follow-up examination for an earlier 
treatment outcome study (Gortner, Gollan, Dobson, & Jacobson, 1998).  The present paper provides a 
critical review of the controlled studies, and provides a meta-analytic summary of their collective 
findings. The purpose is to help frame policy recommendations at this point in time with respect to BA as 
a font-line stand-alone treatment. 
 
We were guided in our review by the use of “gold standards” for treatment outcome studies 
outlined by Foa and Meadows (1997), and the system for classifying Level of Evidence used by the 
Agency for Health Care Policy and Research (AHCPR).  Foa and Meadows identified seven criteria that 
characterize high quality treatment outcome research.  These included:  
 
1. Clearly defined target symptoms, which involves determining the diagnostic status of 
potential participants, specifying a threshold of symptom severity necessary for 
participation in the study, and determining inclusion and exclusion criteria.  
2. Measures with appropriate levels of reliability and validity.  
3. Blind evaluators should be employed. 
4. Appropriately and adequately trained assessors.   
5. Detailed treatment manuals should be used to guide conduct of each intervention. 
6. Random assignment or stratified random assignment procedures to assign participants to 
treatment conditions. 
7. Treatment adherence assessment to ensure that treatments were carried out as outlined in 
the treatment manual and to ensure that little or no treatment drift occurred. 
 
The AHCPR classification system identifies 5 lettered ratings that characterize the level of 
evidence supporting health care interventions.  These include: 
 
1. Level A – Evidence is based on randomized, well-controlled clinical trials 
2. Level B – Evidence is based on well-designed clinical studies, without randomization or 
placebo comparison. 
3. Level C – Evidence is based on service and naturalistic clinical studies, combined with 
clinical observations that are sufficiently compelling to warrant use of the treatment 
technique or follow the specific recommendation. 
4. Level D – Evidence is based on longstanding widespread clinical practice by 
circumscribed group of clinicians that has not been subjected to empirical tests. 
5. Level F – Evidence is based on recently developed treatment that has not been subjected 
to clinical or empirical tests. 
 
We provide a description of the studies in sufficient detail to permit a “gold standard” analysis, 
followed by a meta-analytic review of the quantitative evidence.  We also apply an AHCPR classification 
level for each study.  We then provide an overall summary of the state of the evidence at this time and 
recommend future research designed to strengthen confidence in this intervention as a font-line 
intervention for MDD. 
 
Jacobson, Dobson, Truax, Addis, Koerner, Gollan, and colleagues (1996) investigated the 
effectiveness of BA in the context of a component analysis of CT.  150 outpatients diagnosed with MDD 
were randomly assigned to receive one of three treatments, all of which were components of Beck’s CT 
package: BA, BA with a skill teaching component designed to modify automatic thoughts (AT), or the 
full CT package.  Assessments were conducted by trained and supervised graduate students prior to 
therapy, at the time of termination of therapy, and at 6, 12, 18, and 24-month follow-up examinations.  
Participants were randomly assigned to one of the three aforementioned treatment groups based upon 
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clear inclusion criteria.  The BA treatment condition involved daily activity monitoring, assessment of 
pleasure and mastery when engaging in various activities, assignment of tasks of increasing difficulty, 
cognitive rehearsal and discussion of scheduled activities, discussion of specific problems and provision 
of behavior therapy techniques to remedy the problems, and social skills training.  The AT treatment 
condition involved all of the components from the BA condition, in addition to noticing mood shifts 
during session and inquiring about the thoughts that occurred before the mood shift, completing daily 
thought records, reexamining and discussing thoughts clients made during certain situations and 
determining if the conclusions made were warranted, helping clients to learn to respond more 
appropriately to negative thinking, and examining attributional mistakes in terms of successes and failures 
in the patients’ lives.  The CT condition involved all the components from the AT condition, in addition 
to use of the “downward arrow” technique, the identification of core beliefs, the identification of 
alterative core beliefs, and discussion of the advantages and disadvantages and short-term and long-term 
consequences of certain core beliefs.  All treatments were administered by four experienced cognitive 
therapists, all of whom had participated in at least one previous clinical trial in which they served as 
cognitive therapists and all of whom had been trained for a year prior to the beginning of the study.  The 
data obtained from the study indicated that CT was no more effective than BA or AT.  There were no 
significant differences between the two primary outcome measures at post-test or six-month follow-up.  
All groups had maintained most of the gains made in treatment at six-month follow-up.  There were also 
no significant differences between the number of individuals meeting criteria for improvement or 
recovery.  Finally, the BA and AT conditions were equally as effective as the CT condition at modifying 
negative thoughts and maladaptive attributional styles, though in the case of BA these features were not 
specifically targeted. 
 
Gortner, Gollan, Dobson, and Jacobson (1998) presented the two-year follow-up data for the 
Jacobson et al. (1996) study.  All three treatments led to lasting change, with no one treatment 
outperforming the other two.  There was no significant difference between relapse rates or time to first 
relapse after treatment between the three groups.  Finally, there was no significant difference between the 
number of “well weeks” (weeks during which participants experienced minimal or no depressive 
symptoms), with 75% of the weeks during the two-year follow up categorized as “well weeks” across all 
three groups.  
 
The Jacobson et al. (1996) investigation met all seven of the “gold standards” of treatment 
outcome studies.  Diagnostic status was ascertained through the administration of the Structured Clinical 
Interview for DSM-III-R Axis I Disorders and severity was determined through scores on the Beck 
Depression Inventory and the Hamilton Rating Scale for Depression.  Inclusion and exclusion criteria 
were clearly delineated.  The two primary outcome measures for the study, the Beck Depression 
Inventory (BDI) and the Hamilton Rating Scale for Depression (HRSD), have good psychometric 
properties.  The individuals conducting assessments were extensively trained and supervised and were not 
the same individuals that were administering treatment.  Furthermore, interrater reliability was .9 for 
diagnoses made using the Structured Clinical Interview for DSM-III-R Axis I Disorders (SCID-IV).  
Random assignment procedures were employed to assign individuals to treatment groups.  Manuals were 
completed for each of the treatment groups and were based on the original CT manual.  Finally, therapists 
were extensively monitored for adherence to treatment protocol.  Treatment integrity was assessed by 
independent raters who listened to audiotapes of 20% of the treatment sessions.  Any protocol violations 
were expeditiously addressed.  Monthly meetings also occurred with two of the authors to discuss 
protocol and treatment integrity issues.  In addition to monitoring for adherence, therapist competence 
was also measured using the Cognitive Therapy Scale, and all four therapists were above cutoff scores 
necessary to determine competence.  This investigation warrants an AHCPR rating of “A”, indicating that 
the “evidence is based upon a randomized, well-controlled clinical trial for individuals” with MDD. 
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Hopko, Lejuez, LePage, Hopko, and McNeil (2003) conducted a randomized pilot trial of Brief 
BA with 25 depressed individuals in an inpatient psychiatric hospital.  Assessments using the BDI and 
diagnostic interviews were conducted prior the to first session. The  BDI was repeated at post-treatment 
on day 14 or at discharge.  Patients were randomly assigned to receive Brief BA or standard supportive 
treatment typically provided in the hospital.  In both conditions, patients were enrolled in treatment for 
two weeks or until discharge and during this time, were seen three times per week for 20 minutes by a 
master-level clinician.  The master level clinicians had extensive training and experience with cognitive-
behavioral interventions and were monitored for adherence to the treatment protocol through weekly 
supervision meetings with a licensed clinical psychologist with familiarity with BA principles.  All 
patients also received antidepressant medication.  In the Brief BA group the function of depressed 
behavior was assessed, strategies for reducing reinforcement for depressed behavior were introduced, a 
treatment rationale was provided, and an activity hierarchy was constructed and then followed in a 
systematic fashion.  Furthermore, tokens were provided to patients contingently on the basis of 
completion of Brief BA for treatment-related goals.  In the standard supportive treatment group, patients 
engaged in nondirective discussion in which they were encouraged to share their experiences and discuss 
their problems by their clinician.  Patients in this condition were yoked to individuals in Brief BA such 
that they received tokens in a noncontingent manner.  The data collected indicated that individuals in the 
Brief BA group had significantly greater improvement in BDI scores from pre-treatment to post-treatment 
than those individuals in the standard supportive treatment condition.  Furthermore, a large effect size was 
obtained for individuals in the Brief BA group. 
 
The Hopko et al. (2003) study clearly met two, and possibly three, of the seven “gold standards” 
for treatment outcome studies. The only outcome measure used in this study, the BDI, has adequate 
psychometric properties. Random assignment procedures were employed.  In terms of treatment integrity, 
the individuals administering the behavioral activation intervention had weekly supervision meetings with 
a licensed psychologist with extensive knowledge of the behavioral activation protocol. The expectation 
was that these supervision meetings would be used to monitor treatment adherence.  However, no 
measures of treatment integrity were reported. .  This investigation warrants an AHCPR rating of “A/B”, 
indicating that the Evidence is based on a well-designed clinical study, without randomization or placebo 
comparison.” The study did not include a complete description of the inpatient sample and lack integrity 
measures that would have been expected of a higher classified trial. 
 
Cullen, Spates, Pagoto, and Doran (2006) randomly assigned 25 individuals diagnosed with 
MDD (using the Structure Clinical Interview for DSM-IV or SCID-IV) to 10 weeks of individual BA 
therapy or 6 weeks of no treatment in the waitlist-control condition.  Assessments, using the SCID-IV, 
BDI and Revised Hamilton Rating Scale for Depression (RHRSD) were conducted at pre-treatment, post-
treatment, and three-month follow-up by doctoral students in clinical or counseling psychology.  
Furthermore, individuals who were assigned to the waitlist-control condition were assessed bi-weekly 
with the BDI – II and also given a full assessment (BDI, RHRSD) at the end of the wait period.  
Individuals once assigned to the BA treatment group, were administered the BDI – II on a weekly basis.  
The BA treatment protocol used was similar to that implemented by Jacobson and colleagues (1996).  
Sessions involved the administration of the BDI– II, a review of homework, addressing topics on the 
agenda for the day, a review of the topics covered, and the assignment of homework.  Those individuals 
assigned to the waitlist condition were told that they were undergoing an “assessment phase” prior to 
treatment.  These individuals came to the clinic on a bi-weekly basis for six weeks in order to complete 
the BDI– II.  The conclusion were that BA led to clinically and statistically significant reductions in levels 
of depression symptoms (BDI-II and HRSD) and formal diagnoses of MDD (SCID-IV) in comparison to 
the waitlist comparison. 
 
The Cullen et al. (2006) study meets all seven of the “gold standards” of treatment outcome 
studies.  The SCID-IV was used to assess if participants met criteria for MDD and the BDI – II, and the 
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RHRSD were used to assess the severity of depression symptoms.  Inclusion and exclusion criteria were 
explicitly described. Random assignment procedures were employed.  The three primary outcome 
measures used in this study all have adequate psychometric properties.  Evaluators were not the same 
individuals who were administering treatment and were adequately trained. Therapists were trained for 12 
hours in behavioral activation techniques and were then given protocol outlines to guide the 
administration of treatment.  Treatment adherence was monitored through videotape review of 11% of all 
therapy sessions.  Review of these tapes indicated that therapists were adhering strongly to treatment 
protocol.  In addition, weekly research team meetings were held to discuss individual cases and as a 
means of preventing therapist drift. This investigation warrants an AHCPR rating of “A”, indicating that 
the “evidence is based upon a randomized, well-controlled clinical trial for individuals” with MDD. 
However the study suffered from a small sample size and warrants replication to establish confidence it 
its conclusions. 
 
Studies of group BA  
 
Porter, Spates, and Smitham (2004) investigated the effectiveness of BA group therapy (BAGT) 
for individuals seeking mental health services for depression at rural community mental health agencies.  
Assessments using the SCID-IV, RHRSD and the BDI-II were conducted at pre-treatment, post-
treatment, and three-month follow-up. Additionally, the BDI– II was administered on a weekly basis for 
all individuals once assigned to BAGT.  Individuals who were assigned to the waitlist group were also 
assessed at the beginning and the end of the waiting period.  37 individuals were randomly assigned to 
either BAGT or a four- to six-week waitlist group.  The BAGT condition was administered by eight staff 
therapists who had degrees in either social work or psychology and who were licensed professionals.  The 
BAGT protocol was heavily based on that in the Jacobson et al. (1996) study.  Treatment sessions were 
led by two co-therapists and attended by six to ten individuals.  Sessions were 95 minutes long.  Data 
from this study indicated that BAGT produced statistically and clinically significant reductions in 
symptoms of depression.  Furthermore, those individuals assigned to the waitlist group did not improve 
during their time on the waitlist, but did improve once they received the BAGT.  The data also indicated 
that there was a statistically significant decrease in the number of individuals who met diagnostic criteria 
for depression from pre-test to the three-month follow-up assessment. 
 
The Porter, Spates, and Smitham (2004) study met six of the seven of the “gold standards” of 
treatment outcome studies.  The SCID-IV was used to determine the presence or absence of a diagnosis of 
MDD.  The BDI – II and the RHRSD were used to assess the level of symptom severity. Random 
assignment procedures were employed.  Inclusion and exclusion criteria were clearly delineated.  The 
measures used, all have adequate psychometric properties.  Independent evaluators performed the 
assessments and were trained.  A detailed BAGT manual gave step-by-step instructions on how to 
implement each phase of treatment and was provided to all therapists, along with booster sessions at 2-3 
month intervals. Finally, although therapists were extensively trained, and the authors communicated 
regularly with therapists about delivering the intervention, no measures of treatment integrity were taken. 
This investigation warrants an AHCPR rating of “A”, indicating that the “evidence is based upon a 
randomized, well-controlled clinical trial for individuals” with MDD. 
 
Unpublished Studies of BA 
 
Wright, Spates, Bloem, DeViva, and Pope (2003) conducted a study assessing the effectiveness 
of behavioral activation administered in a group format to 62 veterans on a Specialized Inpatient PTSD 
Unit in a Veteran Affairs Medical Center. The participants presented with co-morbid PTSD and MDD.  
While staying on the Unit, patients typically completed three treatment tracks.  The C-track was a 22-day 
program involving education and stabilization.  The R-track was a 28-day program consisting of further 
education and beginning to address the trauma recovery process.  The S-track was a 56-day program, 
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focusing specifically on trauma, and involving continued education.  Although a therapy group met 
multiple times a week in each track, depression was not characteristically or explicitly addressed as part 
of treatment.  In this study, the BAGT intervention was integrated in to the R-track.  Prior to admission to 
the unit, all individuals were assessed to ensure that they met criteria for a diagnosis of PTSD.  
Assessments pertaining to the study were conducted at pre-treatment, post-treatment, one-month follow-
up, and two-month follow-up.  Upon entering the unit in a group cohort, participants were randomly 
assigned with the rest of their cohort to either the BAGT group or a comparison group, which received 
standard treatment of classes and group therapy.  Three cohorts were assigned to the BAGT group and 
four cohorts were assigned to the comparison (Treatment as Usual) group.  The BAGT group met twice a 
week and was run by a psychology intern and staff psychologist.  In regard to content, two to three 
psychoeducational topics were discussed each week, including standard skill-sets indicated in the BA 
protocol.  During the group therapy, comprehension of these topics was assessed, relevant examples were 
elicited, and homework was assigned and reviewed.  In addition to receiving BAGT, individuals assigned 
to this condition also attended the same classes and group therapy offered to the comparison group.  The 
results indicated that on all measures of depression, individuals in the BAGT treatment group showed 
significant reductions in symptoms of depression from pre-treatment to two-month follow-up, whereas 
individuals in the comparison group did not.  In the BAGT group, there was an increase in scores on 
measures of depression from post-treatment to one-month follow-up, although these scores decreased by 
two-month follow-up.  Neither group showed significant changes in measure of PTSD.  Finally, this study 
found a strong positive correlation between patient completion of homework assignments and reduced 
symptoms at posttest and follow-up evaluations. 
 
The Wright et al. (2003) investigation met four of the seven “gold standards” of treatment 
outcome studies.  Although diagnostic status of PTSD and inclusion and exclusion criteria was assessed 
during the admissions process (instead of by the research team), a diagnosis of MDD and level of 
symptom severity were determined by the research team.  The primary outcome measures used in the 
study (the BDI – II, the RHRSD, Posttraumatic Stress Diagnostic Scale (PDS), and the Mississippi Scale 
for Combat-Related PTSD (MSC-RPTSD) all have adequate psychometric properties.  Assessors were 
properly trained, however because of their involvement on the unit, they may not have been blind to 
treatment condition.  The manual used in this study was based on the manual used in the Jacobson et al. 
(1996), but was modified such that it was appropriate for use in group, rather than individual, therapy.  
Although cohorts of individuals were randomly assigned to treatment conditions, the individuals 
themselves were not.  Finally, although therapists provided ratings of their own treatment adherence and 
although these ratings were relatively high (91% and 85%), no measures of treatment adherence were 
taken by independent evaluators. This investigation warrants an AHCPR rating of “A/B”, indicating that 
the “evidence is based upon a randomized, well-controlled clinical trial for individuals” with MDD.  This 
investigation was limited by a relatively small sample size, integrity assessment, and a weaker 
randomization procedure, and thus replication is required to establish confidence in its findings. 
 
Dimidjian (2005) conducted a study comparing the efficacy of BA, CT, antidepressant 
medication (Paroxetine), and pill-placebo in the treatment of MDD.  Assessments were conducted at pre-
treatment, mid-treatment (eight weeks), and post-treatment (16 weeks), and at other points during 
treatment as clinical indicated (for example, in instances of early termination).  241 individuals were 
randomly assigned to one of the four aforementioned conditions.  Three therapists provided treatment in 
the BA condition.  Therapists in this condition received both on-site and off-site supervision.  Individuals 
assigned to this condition received a maximum of 24 50-minute sessions, with sessions held biweekly for 
the first eight weeks and weekly for the final eight weeks.  The BA treatment was an expanded version of 
the BA treatment used in the Jacobson et al. (1996) investigation.  The components borrowed from the 
treatment used in Jacobson et al. included self-monitoring, activity scheduling, ratings of pleasure and 
mastery when engaging in certain activities, exploring alternative behaviors related to goal-setting, and 
role playing to address behavioral deficits.  The components added to treatment for this study included the 
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assessment and treatment of avoidance behaviors, establishing and maintaining a regular routine, the 
explicit targeting of rumination, a behavioral case conceptualization, and behavioral treatment rationale.  
Three therapists provided CT.  All therapists in this condition had served as cognitive therapists in prior 
studies and were supervised both on-site and off-site on a weekly basis.  Individuals in this condition 
received the same number and length of therapy sessions as those individuals assigned to the BA 
treatment.  The CT provided in this study was the standard form recommended by Beck and as such, 
explicitly targeted behavioral dysfunction, situation specific negative thinking and cognitive distortions, 
and underlying dysfunctional beliefs.  Five board-certified pharmacotherapists provided services in the 
antidepressant medication and pill-placebo conditions.  These individuals were trained and supervised by 
an experienced pharmacotherapy researcher for the duration of the study.  The two conditions were triple -
blind for the first eight weeks of the study, but at eight weeks the blind was broken and individuals 
assigned to the pill-placebo condition were offered their choice of treatment.  The antidepressant 
medication condition was then conducted in a single-blind fashion for the remaining eight weeks of the 
study.  Individuals in these two conditions were seen weekly for the first four weeks and biweekly for the 
remainder of the study following the first four weeks.  The first session was 30 to 45 minutes and the 
subsequent sessions were 30 minutes.  Typical sessions included the administration of the RHRSD, 
inquiries about treatment response, side effects, non-study medications, and involved renewals or 
modifications of pill dosages.  The findings from this study indicated that for those individuals who were 
in the high severity subgroup, BA and antidepressant medications performed equally well and 
outperformed CT.  However, for individuals who were in the low severity subgroup, all treatments led to 
significant improvement over time, with no differential effects seen for any active treatment in particular. 
 
The Dimidjian (2005) investigation met all seven of the “gold standards” for treatment outcome 
studies.  A diagnosis of MDD was made through the use of the SCID-IV, and severity of depression was 
measured through the use of both the BDI– II and the RHRSD. .  Stratified random assignment 
procedures utilizing symptom severity as the basis for stratification were employed to assign participants 
to groups. Inclusion and exclusion criteria were also explicitly stated.  The two primary outcome 
measures in the study (the BDI– II and the RHRSD) both have adequate psychometric properties.  All 
evaluators were independent of treatment administration, and all evaluators were blind to the treatment 
conditions.  Furthermore, all evaluators were trained, certified, and monitored through weekly supervision 
meetings to prevent any evaluator drift.  A detailed treatment manual was used.  Finally, individuals who 
were blind to treatment condition monitored treatment adherence through ratings of the presence or 
absence of techniques appropriate to condition.  Ratings of competence were also made in the CT and 
antidepressant medication conditions.  Ratings indicated that therapists were adhering strongly to 
treatment protocol and were administering their respective treatments in a competent manner. This 
investigation warrants an AHCPR rating of “A”, indicating that the “evidence is based upon a 
randomized, well-controlled clinical trial for individuals” with MDD. 
 
Non-experimental studies 
 
 Hopko, Armento, Hunt, Bell, and Lejuez (2005) conducted a preliminary clinical trial of Brief 
BA Treatment for Depression with six individuals diagnosed with cancer and MDD.  Undergraduate 
research assistants and graduate students who were supervised by the principal investigator completed 
assessments at pre-treatment, post-treatment, and three-month follow-up.  Supervision was conducted 
through the use of audiotapes and discussion, after which a consensus diagnosis was made.  The Brief BA 
Treatment for Depression consisted of nine one-hour sessions covering psychoeducation, explanation of 
the treatment rationale, activity and goal selection, and behavioral activation.  Treatment was conducted 
by two clinical psychology graduate students who were supervised by the principal investigator through 
an audiotape review process.  Ratings of therapist competence and therapist adherence to the treatment 
protocol were conducted for 20% of the sessions and indicated that the therapists involved in the study 
administered the treatment competently and as outlined in the treatment protocol.  The six patients 
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involved in the study received a treatment adherence score of 78%, indicating that the patients completed 
an average of 78% of the behavioral assignments.  The data collected indicated significant pre-treatment 
to post-treatment change on measures of depression, quality of life, and medical outcomes, yielding 
moderate-to-large effect sizes.  Furthermore, these gains were maintained at the three-month follow-up 
assessment, and the non-significant gains in somatic anxiety and bodily pain measures observed from pre-
treatment to post-treatment assessment improved to clinically significant gains by this follow-up 
assessment.  
 
The Hopko et al. (2005) investigation met five of the seven of the “gold standards” of treatment 
outcome studies.  Diagnostic status was ascertained through the use of the SCID –IV, and a severity 
criterion for MDD was specified for inclusion in the study.  Inclusion and exclusion criteria were clearly 
delineated.  The primary outcome measures, which included the BDI – II, the RHRSD, and the Center for 
Epidemiological Studies of Depression Scale all have solid psychometric properties.  The individuals who 
administered assessments were independent of treatment administration.  No explicit mention of a 
treatment manual for use by the therapists was made by the authors.  However, treatment integrity and 
therapist competence were closely monitored.  The only “gold standard” criterion this study failed to meet 
was random assignment to groups.  This study only had one group and as such, random assignment was 
not possible. This investigation warrants an AHCPR rating of “B”, indicating that the Evidence is based 
on well-designed clinical studies, without randomization or placebo comparison” with MDD. 
 
Summary of well-controlled trials 
 
Taken as a whole, this body of research provides good preliminary evidence for the effectiveness 
of BA as a treatment for depression.  On average, these studies met approximately five of the seven of the 
“gold standards” for treatment outcome research, indicating that the quality of research on the efficacy 
and/or effectiveness of BA is adequate but that there is room for improvement.  This small body of 
research had the additional constraint of small sample sizes in several instances, suggesting that more 
research, especially with larger sample sizes, is needed before BA can confidently be raised to the level of 
a frontline intervention of choice for MDD.  Overall the line of investigation supporting this intervention 
warrants an AHCPR mixed classification of “A/B”.  Three investigations achieved the highest gold 
standard ratings (7) and AHCPR classification (A), while most others achieve an AHCPR classification of 
“B”.  The most consistent weakness across studies entailed small sample sizes.  To that end, we now 
address the collective evidence vis-à-vis a meta-analytic review of these same investigations.  This 
analysis will permit an examination of effect sizes for this novel intervention. 
 
Method 
 
Procedure 
 
 Studies were identified via searches of Medline and PsychInfo from 1997 to 2006 using 
“behavioral activation” and “behavior therapy and depression” as keywords.  Reference lists of studies 
pertaining to BA were also scanned for additional studies.  Both published and unpublished studies were 
included in the analysis.  Only treatment studies that included a baseline and at least one follow-up 
assessment point were included in the analysis.  Most studies had end-of-treatment and 3-month 
assessment points, thus our analysis targeted change from baseline to each of these time points.   
 
 Eight studies were included.  Only studies using a standardized measure of depression were 
included and all studies found met this criteria.  The primary focus of this article is the within-subjects 
effects of BA for Major Depressive Disorder.  Two studies randomly assigned participants to BA or wait-
list control (Porter et al. 2004, Cullen et al., 2006) and four studies randomly assigned participants to BA 
or other treatments such as supportive psychotherapy (Hopko et al., 2003), usual care (Wright et al., 
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unpublished), cognitive therapy (Jacobsen et al., 1996; Dimidijian, unpublished), or medication 
(Dimidijian, unpublished).  The 2 remaining studies did not utilize random assignment and were single 
group designs (Hopko et al., 2005; Pagoto et al., unpublished). 
 
Measures 
 
 The primary outcome for all studies was depressive symptomatology which was most often 
measured using the BDI-II and the RHDSD.  Because all but one study utilized both of these measures 
and they are standardized measures of depression, the present analysis reports effect sizes from these 
measures.  
 
Effect Size Calculation 
 
Effect sizes were calculated by computing pre- to post-treatment and pre-treatment to follow-up 
(3-months, unless otherwise stated) differences for the treatment group using Cohen’s d [(? pre -  ? post) / 
SDpooled] and [(? pre -  ? follow-up) / SDpooled]. Cohen’s d was selected as the effect size estimate because it 
permits pre-test – post-test comparisons within studies, allowing for comparisons of effect sizes across 
studies that utilize different types of control conditions. Cohen’s d tends to provide a more conservative 
estimate than other commonly used methods (Rosenthal, 1991).  The small number of studies did not 
allow for BA versus control or BA versus other treatment comparisons. 
 
Average effect sizes were derived within studies by computing the mean effect size for the Beck 
Depression Inventory and Hamilton Depression Rating Scale scores.  Effect sizes were weighted by the 
sample size on which it was based when computing the mean of all effect sizes.  Two studies (Hopko et 
al., 2003; Dimijidian, unpublished) only reported post-treatment scores and were therefore not included in 
the mean effect size calculation for follow-up time points.   One study reported data on both low and high 
symptom severity levels (Dimijidian, unpublished), thus effect sizes for both subgroups are reported.  
 
Results of Meta Analysis 
 
 Effects sizes for improvement in BDI-II scores ranged from medium to very large (.49 to 4.03) at 
post-treatment and small to very large (.3 to 2.92) at follow-up (see Table 2).  Of the 8 studies, 6 reported 
very large effect sizes (> 1.0) for BDI-II scores at post-treatment and 5 of 6 reported very large effect 
sizes at follow-up.  For HDRS scores effect sizes ranged from large to very large (.83 to 3.29) at post-
treatment and large to very large (.96 to 2.48) at follow-up.  All 7 studies utilizing the HDRS reported 
large or very large effect sizes at both post-treatment and follow-up.   
 
Attrition 
 
 Attrition rates for the 7 studies that involved outpatient treatment ranged from 9-33%, with 
smaller studies having higher rates of attrition, generally.  The mean attrition rate across these 7 studies 
was 18.71%, which is comparable to attrition rates reported in other depression psychotherapy (Last 
1985; Satterfield, 1998:) and pharmacotherapy research (Aikens, Nease, Nau, Klinkman, & Schwenk, 
2005). 
 
Summary of Meta Analysis 
 
 To date, only a small number of treatment studies have been conducted on BA treatment for 
depression.  Those studies have revealed significant and fairly large effect sizes on standardized measures 
of depression. In fact there appears to be a strong association of number of sessions required in the 
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protocol and effect size achieved (range 6 to 24 visits). The average attrition rate was fairly comparable 
with other psychotherapies and better than pharmacotherapies for depression.   
 
 Although these initial studies of the efficacy of BA have had consistently positive outcomes, 
larger randomized trials comparing BA to other therapeutic modalities are needed.   
 
 
Table 1.  Mean Pre- Versus Post-Treatment and Pre- Versus Follow-Up Effect Sizes 
______________________________________________________________________ 
                          Effect Size (d) 
    ___________________________________________ 
    Weighted Mean SD  95% CI 
     ____________________________________________ 
BDI-II 
 Pre-post  2.11   1.14  1.13, 3.15 
 Pre-Follow-up  1.83   .93  .78, 2.74 
 
HDRS 
 Pre-post  1.91   .88  1.23, 2.70 
 Pre-Follow-up  1.78   .64  1.06, 2.40 
________________________________________________________________________ 
    Table 2.  Characteristics of studies included in the present meta analysis 
Authors Sample 
size (# 
receiving 
BA) 
Comparison 
groups  
Treatment 
modality 
Number 
of visits 
Assessmen
t points 
Measures Effect 
size (pre-
post, pre- 
follow-
up) 
Attriti
on 
rate 
Cullen et al 
2006 
N=25 (25)  Wait-list 
control 
Individual 10 Pre-, Post-
treatment, 3 
months 
BDI-II, 
HDRS 
BDI (1.82, 
1.74) 
HDRS 
(.83, .96) 
32% 
Pagoto et al 
unpub’ed 
N=14 (14) None Individual 12 Pre-, Post-
treatment, 
4-months 
BDI-II 
and 
HDRS 
BDI (3.19, 
2.01) 
HDRS 
(2.82, 
2.05) 
14% 
Dimidijian 
et al 
N=241 
(43) 
Cognitive 
therapy, 
paroxetine, 
placebo 
Individual 24  Pre-, post-
treatment 
BDI-II 
and 
HDRS 
BDI low 
severity 
(2.41) 
high 
severity 
(4.03) 
HDRS 
low 
severity 
(2.05) 
high 
severity 
(3.29) 
9% 
Hopko et al 
2005 
N=6 (6) None Individual 9 Pre-, Post-
treatment, 
3-months 
BDI-II, 
HDRS, 
CES-D 
BDI-II 
(1.7, 2.46) 
HDRS 
33% 
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(1.7, 2.21) 
 
Porter et al, 
2004 
N=30 (30) Wait-list 
control 
Group 10 Pre-, Post- 
and 3-
months 
BDI-II, 
HDRS 
BDI-II 
(.71, 
1..17) 
HDRS 
(1.56, 
1.72) 
13% 
Hopko et al 
2003 
N=25 (10) Supportive 
psychotherapy 
Individual 6 Pre-, post-
treatment 
BDI-II  BDI-II 
(1.56, na); 
differentia
l effect 
with SP = 
.73 
0% 
(inpati
ent) 
Jacobsen et 
al 1996 
N=152 
(57) 
CBT, AT  Individual 20 Pre-, post-, 
6-, 12-, 18-, 
24 mo 
LIFE, 
BDI-II, 
HDRS 
BDI (2.78, 
2.92) 
HDRS 
(2.58, 
2.48) 
10% 
Wright et 
al unpub’ed 
N=62 (30) Usual care Group 8 Pre-, post-, 
2 months 
BDI, 
HDRS 
BDI (.49, 
.30) 
HDRS 
(.93, .98) 
20% 
 
Recommendations for future research 
 
The present review reveals that BA for MDD meets criteria as an empirically supported 
intervention.  More than two independent, well controlled investigations have been completed, all 
favoring BA over a controlled comparison, i.e. waitlist or alternative treatment or showing its equivalence 
to an existing frontline intervention.  The attrition rates for BA are comparable on average to existing 
frontline interventions as well and better than rates achieved in most medication trials. The target 
populations so far have included rural low-SES sample, veterans sample with comorbid PTSD, a sample 
of MDD comorbid with cancer diagnoses, a sample of MDD comorbid with obesity diagnosis, and an 
undifferentiated sample of subjects recruited to a trial at an academic clinical research site. The quality of 
investigations has been moderate to very good in terms of gold standards for treatment outcome 
investigations.  These facts not withstanding, it is clear that additional large-scale trials are needed to 
establish confidence in this intervention as a front line treatment of choice.  The following types of studies 
are recommended. 
 
More studies are needed that compare BA with focused active psychological interventions. For 
example additional studies that compare BA to CBT or CT are necessary.  This kind of investigation 
would essentially establish a cross-validation of BA with reference to the original Jacobson et al. study. 
Additional studies should use a common BA treatment manual chosen perhaps from among those 
demonstrating efficacy and stronger effect sizes with shorter intervention time periods (8-12 weeks), 
rather than the original Jacobson manual. 
 
Studies should be conducted that compare BA to evidence-based medication interventions, alone 
and in combination with balanced lead-in periods (those starting with BA versus those starting with 
medications).  Patient severity levels should be taken into account during random assignment to assure 
balance within samples. 
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Attention should be given to SES levels in patient comparisons, as a potential advantage of BA 
might be its relative simplicity and suitability to individuals without sophisticated verbal abilities as might 
be found among low SES individuals. 
 
Given the promise of efficacy shown so far with BAGT, there should be addition studies with 
larger sample sizes that utilize this modality as a primary intervention, a follow along intervention, and a 
‘salvage’ intervention during trials due to its potential cost effectiveness.  
 
Continued study of BA in relation to comorbid medical and psychological conditions is also 
warranted, given the prevalence of MDD with such conditions as Posttraumatic Stress Disorder, anxiety 
disorders, and a vast array of primary medical conditions. 
   
Finally, researchers and clinicians should not lose site of the fact that BA’s original emergence in 
the context of a dismantling study of CBT provides support for it as a parsimonious accounting as the 
active ingredient in CBT / CT.  In this respect, BA might be considered the central ingredient to be 
heavily accentuated when attempting to increase the effective “dosage” of the full CBT/CT protocol. 
Research investigators and clinicians who address recalcitrant and unremitting MDD in the face of 
standard manualized CBT might consider giving greater emphasis to the BA component when working 
with these difficult patients. 
 
Policy Implications 
 
 BA is an empirically supported intervention for MDD.  It should be practiced by trained and 
competent clinicians, and insurers should recognize it as an efficacious therapy for Major Depressive 
Disorder. As an emerging practice it warrants continued research by clinical investigators so that a 
determination can be made as to what types of patients respond best to this intervention in comparison to 
other efficacious treatments. NIMH’s interest in this therapeutic intervention lays the groundwork for 
potential funding for larger scale studies. 
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